The Latest Breaking News from Novo Nordisk

Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback.  It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two…

Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the disease in a trial. Meanwhile, Germany's Bayer said their stroke-prevention drug showed positive results, pushing the share price through the roof.

It's a tough time for the job market

Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.

Novo Nordisk's new pricing for its GLP-1 drugs is a strategic pivot to capture a mass market, pressure rivals, and secure long-term market dominance.

Novo Nordisk cuts Wegovy's price and commits fully to its upcoming weight-loss pill to stay competitive in the fast-growing obesity drug market.

Novo Nordisk's new $199 offer for Ozempic and Wegovy aims to improve access for obesity and diabetes treatments, but experts warn of potential serious side effects.

Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited-time price of $199 per month to new self-pay patients between now and March 31, 2026.

Newly installed Chairperson Lars Rebien Sorensen signaled a rapid shift in governance and strategic direction at Novo Nordisk A/S (NYSE:NVO), saying he intends to strengthen the board's pharmaceutical and over-the-counter expertise while easing concerns about the sweeping power now held by the Novo Nordisk Foundation.